Simulations Plus

Simulations Plus Forward P/E

The Forward P/E Ratio of Simulations Plus (SLP) as of Sep 27, 2026 is -3.83. In the previous year, Forward P/E Ratio was 24.87 — a change of -115.38% (lower).

Forward P/E

-3.83

YoY

-115.38%

Last updated:

Forward P/E Ratio of Simulations Plus is 2026 -3.83 . Forward P/E Ratio of Simulations Plus was 2025 24.87 . It decreases by -115.38% lower compared to the previous year.

The Simulations Plus Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2018
27.71 USD
Jan 1, 2019
28.85 USD
Jan 1, 2020
26.53 USD
Jan 1, 2021
25.31 USD
Jan 1, 2022
19.84 USD
Jan 1, 2023
24.86 USD
Jan 1, 2024
24.87 USD
Jan 1, 2025
-3.83 USD
The Simulations Plus Forward P/E history
YEARForward P/EYoY
-3.83-115.38%
24.87+0.07%
24.86+25.32%
19.84-21.64%
25.31-4.60%
26.53-8.03%
28.85+4.10%
27.71-35.22%
42.78-14.47%
50.02-22.37%
64.43-21.27%
81.84—
Access this data via the Eulerpool API
Get Free API Key

Simulations Plus Stock analysis

What does Simulations Plus do? Simulations Plus Inc is a company that offers software and services for the pharmaceutical industry. The company was founded in 1996 by Dr. Walt Woltosz and is headquartered in Lancaster, California. Simulations Plus began with the development of GastroPlus, a software that simulates the effects of drugs in the body using mathematical models. This software quickly became an important tool for the pharmaceutical industry to improve the effectiveness and safety of medications. Simulations Plus's business model is based on providing high-quality software and services for the pharmaceutical industry. They offer a wide range of products aimed at improving the effectiveness and safety of drugs by optimizing drug development and design. These products include software for simulating and analyzing the pharmacokinetics and dynamics of medications, a model for detecting and avoiding potential life-threatening liver damage, a cloud-based platform for simplifying the work of scientists and researchers, and services to assist with regulatory affairs and obtaining product approvals. Simulations Plus is known for its high-quality products and excellent customer support, and their various divisions and products contribute to improving the effectiveness and safety of medications, ultimately promoting patient health. The translation of the text is: "Simulations Plus Inc is a company that offers software and services for the pharmaceutical industry. The company was founded in 1996 by Dr. Walt Woltosz and is headquartered in Lancaster, California. Simulations Plus began with the development of GastroPlus, a software that simulates the effects of drugs in the body using mathematical models. This software quickly became an important tool for the pharmaceutical industry to improve the effectiveness and safety of medications. Simulations Plus's business model is based on providing high-quality software and services for the pharmaceutical industry. They offer a wide range of products aimed at improving the effectiveness and safety of drugs by optimizing drug development and design. These products include software for simulating and analyzing the pharmacokinetics and dynamics of medications, a model for detecting and avoiding potential life-threatening liver damage, a cloud-based platform for simplifying the work of scientists and researchers, and services to assist with regulatory affairs and obtaining product approvals. Simulations Plus is known for its high-quality products and excellent customer support, and their various divisions and products contribute to improving the effectiveness and safety of medications, ultimately promoting patient health." Simulations Plus is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Simulations Plus stock

Forward P/E Ratio of Simulations Plus is -3.83 in 2026.

Forward P/E Ratio of Simulations Plus changed from 24.87 to -3.83, representing a -115.38% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Simulations Plus since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Simulations Plus with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API
Get Free API Key

Valuation — Simulations Plus

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Simulations Plus